array:24 [ "pii" => "S0213005X17303221" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2017.10.022" "estado" => "S300" "fechaPublicacion" => "2018-12-01" "aid" => "1774" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:607-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 796 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 505 "PDF" => 290 ] ] "itemSiguiente" => array:19 [ "pii" => "S0213005X17303671" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2017.10.026" "estado" => "S300" "fechaPublicacion" => "2018-12-01" "aid" => "1785" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:612-20" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1080 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 687 "PDF" => 391 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Evolución de la enfermedad neumocócica invasora y sus serotipos en la Comunidad de Madrid" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "612" "paginaFinal" => "620" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Trends of invasive pneumococcal disease and its serotypes in the Autonomous Community of Madrid" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2383 "Ancho" => 3171 "Tamanyo" => 435545 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Incidencia de enfermedad neumocócica invasora causada por los serotipos adicionales de VCN13 por grupo de edad. Comunidad de Madrid. Años 2008 a 2015.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pello Latasa Zamalloa, Juan Carlos Sanz Moreno, María Ordobás Gavín, María Dolores Barranco Ordoñez, Esther Insúa Marisquerena, Ángel Gil de Miguel, Abelardo Claudio Fernández Chávez, Luis García-Comas" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Pello" "apellidos" => "Latasa Zamalloa" ] 1 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Sanz Moreno" ] 2 => array:2 [ "nombre" => "María" "apellidos" => "Ordobás Gavín" ] 3 => array:2 [ "nombre" => "María Dolores" "apellidos" => "Barranco Ordoñez" ] 4 => array:2 [ "nombre" => "Esther" "apellidos" => "Insúa Marisquerena" ] 5 => array:2 [ "nombre" => "Ángel" "apellidos" => "Gil de Miguel" ] 6 => array:2 [ "nombre" => "Abelardo Claudio" "apellidos" => "Fernández Chávez" ] 7 => array:2 [ "nombre" => "Luis" "apellidos" => "García-Comas" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529993X1830193X" "doi" => "10.1016/j.eimce.2018.07.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X1830193X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17303671?idApp=UINPBA00004N" "url" => "/0213005X/0000003600000010/v2_201812190632/S0213005X17303671/v2_201812190632/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X18302568" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2018.07.012" "estado" => "S300" "fechaPublicacion" => "2018-12-01" "aid" => "1912" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:605-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 897 "formatos" => array:2 [ "HTML" => 471 "PDF" => 426 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Pneumococcal disease and conjugate vaccines" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "605" "paginaFinal" => "606" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedades neumocócicas y vacunas conjugadas" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jordi Càmara, Carmen Ardanuy" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jordi" "apellidos" => "Càmara" ] 1 => array:2 [ "nombre" => "Carmen" "apellidos" => "Ardanuy" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X18302568?idApp=UINPBA00004N" "url" => "/0213005X/0000003600000010/v2_201812190632/S0213005X18302568/v2_201812190632/en/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S0213005X18302568" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2018.07.012" "estado" => "S300" "fechaPublicacion" => "2018-12-01" "aid" => "1912" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:605-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 897 "formatos" => array:2 [ "HTML" => 471 "PDF" => 426 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Pneumococcal disease and conjugate vaccines" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "605" "paginaFinal" => "606" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedades neumocócicas y vacunas conjugadas" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jordi Càmara, Carmen Ardanuy" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jordi" "apellidos" => "Càmara" ] 1 => array:2 [ "nombre" => "Carmen" "apellidos" => "Ardanuy" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X18302568?idApp=UINPBA00004N" "url" => "/0213005X/0000003600000010/v2_201812190632/S0213005X18302568/v2_201812190632/en/main.assets" ] ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Paediatric invasive pneumococcal disease on the island of Gran Canaria: 16-year prospective study (2001–2016)" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "607" "paginaFinal" => "611" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Milagrosa Santana Hernández, Ione Ahedey Aguiar-Santana, Fernando Artiles Campelo, Elena Colino Gil" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Milagrosa" "apellidos" => "Santana Hernández" "email" => array:1 [ 0 => "misanhery@gobiernodecanarias.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Ione Ahedey" "apellidos" => "Aguiar-Santana" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Fernando" "apellidos" => "Artiles Campelo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Elena" "apellidos" => "Colino Gil" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Unidad de Urgencias de Pediatría, Hospital Universitario Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Microbiología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unidad de Enfermedades Infecciosas, Hospital Universitario Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad neumocócica invasiva pediátrica en la isla de Gran Canaria: estudio prospectivo durante 16 años (2001-2016)" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 753 "Ancho" => 1692 "Tamanyo" => 79540 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Annual distribution of IPD cases and deaths.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Streptococcus pneumoniae</span> is responsible for a large variety of infectious diseases, the most serious of which constitute the group called invasive pneumococcal disease (IPD).</p><p id="par0010" class="elsevierStylePara elsevierViewall">In our country, marketing of paediatric pneumococcal vaccines began in June 2001 with a vaccine (PCV7, Wyeth/Pfizer, Prevenar<span class="elsevierStyleSup">®</span>), that immunized against 7 serotypes (ST), followed by a new vaccine adding 3 more STs in March 2009 (PCV10, GSK, Synflorix<span class="elsevierStyleSup">®</span>) and a last one in June 2010 adding other 3 STs (PCV13 Wyeth/Pfizer, Prevenar13<span class="elsevierStyleSup">®</span>). However, the immunization schedule in our region did not publicly fund pneumococcal vaccination until March 2015 (in a 2<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>1 schedule).</p><p id="par0015" class="elsevierStylePara elsevierViewall">The aim of our study was to calculate the incidence of paediatric IPD in our population, its clinical and epidemiological characteristics, ST distribution, antibiotic resistance, and the evolution in these variables among the years preceeding PCV13 introduction (pre-PCV13 period) and the post-PCV13 period.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Design</span><p id="par0020" class="elsevierStylePara elsevierViewall">Prospective hospital-based study including the 190 patients aged 0–14 years admitted to the only paediatric tertiary referral hospital in the island of Gran Canaria (Hospital Universitario Materno-Infantil de Canarias, Gran Canaria, Spain) between January 2001–December 2016 with confirmed IPD by culture or PCR.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Patients were divided into 3 age groups (<2 years; 2–5 years; and >5 years) and 2 different periods for comparison purposes, January 2001–May 2010 (pre-PCV13 period) and June 2010–March 2016 (post-PCV13 period).</p><p id="par0030" class="elsevierStylePara elsevierViewall">Vaccination status, basic demographic and clinical data were collected. Clinical syndromes were mutually exclusive classified as meningitis, bacteremic pneumonia (BP), pleural effusion (PE), empyema or bacteremia without a focus. The study was approved by the local Ethical Committee and informed consent was not necessary.</p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Identification and serotyping</span><p id="par0035" class="elsevierStylePara elsevierViewall">Sterile samples were collected from all patients: blood (71.1%), cerebrospinal fluid (15.8%) or pleural fluid (13.1%). Identification of <span class="elsevierStyleItalic">S. pneumoniae</span> was performed at the local Service of Microbiology by observing umbilicated α-hemolytic colonies or mucosa on blood agar and sensitive to optochin. In doubtful cases, species was identified by determining the solubility in bile and the agglutination with latex particles coated with specific antiserum (Pneumo-Slidex Test Kit, Biomerieux, Marcy L’Etoile, France). When cerebrospinal or pleural fluid samples did not yield a positive culture, samples were sent to the reference laboratory (National Centre for Microbiology, Majadahonda, Madrid) for identification by a quantitative real time PCR detecting pneumolysin (ply) gene.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Serotyping was performed at the reference laboratory using the Quelling method or PCR methodology<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> when culture was negative. ST was available in 145 cases.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Antibiotic susceptibility tests</span><p id="par0045" class="elsevierStylePara elsevierViewall">Antibiotic susceptibility testing was performed at the local Service of Microbiology by E-test (ABbiodisk, Solna, Sweden) on Müller-Hinton agar with blood for the following antibiotics: penicillin, cefotaxime and erythromycin. The results were reported according to CLSI criteria in force at every time.</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Statistical analysis</span><p id="par0050" class="elsevierStylePara elsevierViewall">To determine the incidences of each period, incidence was considered as a random variable distributed according to a Poisson law. This model assumed that expected incidences were constants at each period. Incidences for each period/year were deduced from the model, which was estimated by the maximum likelihood method, and the results were summarized as number of cases by 100,000 persons. Population data were obtained from the Canary Islands Statistics Institute (ISTAC).</p><p id="par0055" class="elsevierStylePara elsevierViewall">Data were analyzed using SPSS<span class="elsevierStyleSup">®</span> v23 (SPSS, Chicago, Illinois, USA). Differences were assessed using <span class="elsevierStyleItalic">X</span><span class="elsevierStyleSup">2</span> or Fisher's exact test when appropriate. Statistical significance was established at <span class="elsevierStyleItalic">α</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.05 and confidence intervals were calculated.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Results</span><p id="par0060" class="elsevierStylePara elsevierViewall">Demographic characteristics of the study population and distribution of clinical syndromes among study periods are showed in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. During pre-PCV13 period, 152 cases were registered with an average age of 2.5 years, mostly in males (58.6%) and in winter (36.2%). During post-PCV13 period, 38 cases were registered with an average age of 3.1 years and, again, mostly in males (63.2%) and in winter (34.2%).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">Patients were stratified by age group: aged <2 years (59.2% in pre-PCV13 period <span class="elsevierStyleItalic">vs</span> 42.1% in post-PCV13 period); aged 2–5 years (28.9% <span class="elsevierStyleItalic">vs</span> 44.7%); and aged >5 years (11.8% <span class="elsevierStyleItalic">vs</span> 13.2%). The 8 deaths registered occurred during the pre-PCV13 period and mostly in females (60%): a 14 months female, a 10 months male, a 43 months female, and a 119 months female (having an underlying Mondini malformation) died from meningitis; a 11 months female (having an underlying bronchopulmonary dysplasia) and a 10 months female (having an underlying encephalopathy with a non-filiated genetic syndrome) died from BP; a 33 months female died from PE and a 127 months male (having an underlying leukaemia) died from bacteremia.</p><p id="par0070" class="elsevierStylePara elsevierViewall">We found a 66.4% reduction (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001) in the overall incidence rate: from 13.1 (95% CI: 11.2, 15.2)/100,000 in pre-PCV13 period to 4.4 (95% CI: 3.2, 6)/100,000 in post-PCV13 period. This decrease was observed in every age group: from 59.9 (95% CI: 48.8, 73.5)/100,000 to 18.9 (95% CI: 11.8, 30.4)/100,000 (68.4% reduction, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001) in aged <2 years; from 20.4 (95% CI: 15.5, 26.9)/100,000 to 9.9 (95% CI: 6.1, 16.2)/100,000 (51.5% reduction, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.012) in aged 2–5 years; and from 2.4 (95% CI: 1.5, 3.7)/100,000 to 0.8 (95% CI: 0.3, 1.9)/100,000 (66.6% reduction, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.031) in aged >5 years.</p><p id="par0075" class="elsevierStylePara elsevierViewall">The distribution of clinical syndromes among periods was as follows: meningitis (14.5% <span class="elsevierStyleItalic">vs</span> 13.2%), BP (23% <span class="elsevierStyleItalic">vs</span> 15.8%), PE (3.9% <span class="elsevierStyleItalic">vs</span> 18.4%), empyema (4.6% <span class="elsevierStyleItalic">vs</span> 10.5%) and bacteremia without a focus (53.9% <span class="elsevierStyleItalic">vs</span> 42.1%). Variations in BP, empyemas, bacteremia without a focus, and meningitis were not statistically significant. On the other hand, increase of PEs was statistically significant (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.005; 95% CI: 1.7, 17.5) but, when studying cases according to group age, this increase was only observed in children aged <2 years (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.002; 95% CI: 3, 287.9).</p><p id="par0080" class="elsevierStylePara elsevierViewall">5 vaccine failures were observed in pre-PCV13 period (by ST6B, 9V, 14, 18C and 23F) <span class="elsevierStyleItalic">vs</span> 1 (by ST3) in post-PCV13 period. 52 patients did not have the appropriate age for vaccination or there was no vaccine available at that time. From the remaining 138, 80 (58%) were immunized (51 with PCV7 and 29 with PCV13) but only 27 (33.7%) had their age-appropriate doses. In a previous study,<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> PCV7 vaccination coverage in Gran Canaria was reported to be only 25% in 2003 and 48% in 2006. On the other hand, the estimated PCV13 vaccination coverage in 2014 was 49.15% (according to sales data supplied by Wyeth) but after introduction of PCV13 in the publicly funded immunization schedule in our region, it reached 82.2% in 2015 and 96.2% in 2016 (data supplied by the Public Health Directorate of the Canary Islands Health Service).</p><p id="par0085" class="elsevierStylePara elsevierViewall">Annual distribution of IPD cases is showed in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>. When analysing data year by year, we found that in 2007 none of the 9 IPD cases in that year had a PCV7-included ST and, in 2008, when cases were three times the figure of the previous year, only 33% were PCV7-included STs. Moreover, there was a dramatic increase in the number of ST19A cases (10) but, since then, a decline in both ST19A and ST1 was observed, specially after introduction of PCV13 in June 2010. In 2011, the number of recorded IPD cases was the half of that in 2010 (6 <span class="elsevierStyleItalic">vs</span> 12) and the lowest number of cases in our series (4) occurred in 2012.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">The most common STs in pre-PCV13 period were ST19A (23.9% of serotyped cases) and ST14 (14.2%); and ST19A, ST23B and ST24F (12.5% each) in post-PCV13 period. STs showing higher increases between periods were ST24F (0.9% <span class="elsevierStyleItalic">vs</span> 12.5%), ST23B (5.3% <span class="elsevierStyleItalic">vs</span> 12.5%) and ST3 (2.7% <span class="elsevierStyleItalic">vs</span> 9.4%) whereas STs showing higher decreases were ST19A (23.9% <span class="elsevierStyleItalic">vs</span> 12.5%), ST14 (14.2% <span class="elsevierStyleItalic">vs</span> 9.4%) and ST19F (6.2% <span class="elsevierStyleItalic">vs</span> 0%).</p><p id="par0095" class="elsevierStylePara elsevierViewall">Vaccine ST distribution among periods is showed in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>. PCV7-included STs were responsible of 36.3% of IPD cases in pre-PCV13 period <span class="elsevierStyleItalic">vs</span> 12.5% in post-PCV13 period (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; 95% CI: 0.1, 0.8) whereas PCV13-included STs were responsible of 77% of IPD cases in pre-PCV13 period <span class="elsevierStyleItalic">vs</span> 40.6% in post-PCV13 period (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000; 95% CI: 0.1, 0.7). Non-vaccine STs also decreased from 63.7% in pre-PCV13 period to 59.4% in post-PCV13 period.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">It was observed a decrease in the percentage of serotyped cases caused by vaccine STs for bacteremia without a focus (72.1% <span class="elsevierStyleItalic">vs</span> 40%), PE (100% <span class="elsevierStyleItalic">vs</span> 20%), BP (85.7% <span class="elsevierStyleItalic">vs</span> 33.4%), meningitis (50.2% <span class="elsevierStyleItalic">vs 2</span>0%) and empyemas (100% <span class="elsevierStyleItalic">vs</span> 66.6%). However, only 14.2% of empyema cases in pre-PCV13 period were serotyped. The most common STs in bacteremia cases were ST19A (23% <span class="elsevierStyleItalic">vs</span> 13.3%), ST14 (9.8% <span class="elsevierStyleItalic">vs</span> 13.3%) and ST23B (9.8% <span class="elsevierStyleItalic">vs</span> 13.3%). In meningitis, 39.1% of serotyped cases were produced by PCV7-included STs, the most common STs being ST14 and ST18C (13% of serotyped meningitis in both cases). However, they all occurred in pre-PCV13 period whereas none of the serotyped cases in post-PCV13 period were produced by PCV7-included STs. In BP, the overall most common STs were ST19A (29.4% of BP serotyped cases), ST14 (17.6%), ST 19F (8.8%) and ST24F (8.8%) but with ST19A not being responsible of any case in post-PCV13 period.</p><p id="par0105" class="elsevierStylePara elsevierViewall">No resistant cases were found for cefotaxime whereas 9.9% in pre-PCV13 period and 2.6% in post-PCV13 period showed intermediate sensitivity and 90.1% <span class="elsevierStyleItalic">vs</span> 97.4% were sensitive. Overall, 38.88% of all erythromycin resistant cases were attributable to only two STs: ST19A and ST14. Among periods, 57.2% <span class="elsevierStyleItalic">vs</span> 7.9% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000; 95% CI: 4.6, 53) showed resistance, 17.1% <span class="elsevierStyleItalic">vs</span> 47.4% showed intermediate sensitivity and 25.7% <span class="elsevierStyleItalic">vs</span> 44.7% were sensitive. 5.3% <span class="elsevierStyleItalic">vs</span> 0% were resistant to penicillin, 35.5% <span class="elsevierStyleItalic">vs</span> 5.3% showed intermediate sensitivity and 59.2% <span class="elsevierStyleItalic">vs</span> 94.7% were sensitive.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Discussion</span><p id="par0110" class="elsevierStylePara elsevierViewall">A total of 190 cases were recorded, mostly in males aged <2 years and during autumn-winter. This trend was observed in both periods although the mean age slightly increased in the post-PCV13 period.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Since IPD was not a “reportable disease” in Spain prior to the introduction of the different vaccines, no precise data are available on its incidence at that time but some hospital studies estimated it among 31.1–58.8/100,000 in children aged <5 years<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">4–7</span></a> whereas a study in the island of Gran Canaria placed the incidence in 52.7/100,000 in children aged <2 years in 2000.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">Two years after PCV7 introduction in the Spanish regions of the Basque Country and Navarre, with an estimated coverage of 28–45%, the incidence of IPD was reduced by 40% in children aged <2 years and by 37% in children aged <5 years.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> In Gran Canaria, with an estimated coverage of 25%, incidence of IPD reduced by 42.5% in children aged <2 years but increased by 6.3% in children aged <14 years. However, when the incidence in the pre-vaccination period was compared to that in the post-vaccination period until 2006 (with an estimated coverage of 48%), an increase was observed both in children aged <2 years (7.4%) and aged <14 years (27.9%).<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> In other Spanish regions, however, there were few or no differences between the pre-vaccination period and the first post-vaccination years due to the increase in non-PCV7 STs, specially 7F and 19A, although vaccination rates were as low as 30% in some of these studies.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">9,10</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">Following introduction of PCV13, generalized reductions in the incidence of IPD in Spain started to be observed.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">10,11</span></a> In this study, we found an incidence in the island of Gran Canaria of 13.17/100,000 in pre-PCV13 period (59.9 in <2 years, 20.4 in 2–5 years, 2.4 in >5 years) <span class="elsevierStyleItalic">vs</span> 4.4/100,000 in post-PCV13 period (18.9 in <2 years, 9.9 in 2–5 years, 0.8 in >5 years). Incidence therefore reduced among periods both globally (66.4%) and in every age group (68.4% in <2 years, 51.1% in 2–5 years and 66.6% in >5 years). These data are in line with those reported in other countries where a reduction in the incidence of IPD has been observed when compared with the average incidence in the years preceding PCV13 introduction.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">12–16</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">Bacteremias without a focus, BP and meningitis decreased from pre-PCV13 period to post-PCV13 period whereas empyemas increased but these variations did not reach statistical significance. On the other hand, there was an increase of PEs, specially in children aged <2 years (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.002; 95% CI: 3, 287.9). In other countries, however, empyema and PE incidences decreased after PCV13 introduction.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">17</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">During the study, there were different vaccines licensed in our region. However, they were only available for private purchase during most of the study (until March 2015) and publicly funded only onwards. In a previous study,<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> PCV7 vaccination coverage in Gran Canaria was reported to be only 25% in 2003 and 48% in 2006. According to sales data supplied by Wyeth, the estimated PCV13 vaccination coverage in 2014 had only reached 49.15%. A possible explanation to the increase in PEs and empyemas may be a low vaccination rate in our island which would have maintained the secular trend of increasing cases in the last decades.<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">18,19</span></a> A total of 6 vaccine failures (ST3, 6B, 9V, 14, 18C, 23F) were observed, only one in post-PCV13 period due to ST3 for which a lower effectiveness of PCV13 has been suggested.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">16</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">PCV7-included STs have clearly decreased from pre-PCV13 period to post-PCV13 period (36.3% <span class="elsevierStyleItalic">vs</span> 12.5%) and STs added in PCV13 also decreased, but this reduction did not reach statistical significance (40.7% <span class="elsevierStyleItalic">vs</span> 28.1%). STs not included in any of the available vaccines at the time also decreased from 63.1% in pre-PCV13 period to 52.4% in post-PCV13 period. Changes in ST distribution between periods and among clinical syndromes have also been observed although the number of serotyped cases is too low to form a judgement.</p><p id="par0145" class="elsevierStylePara elsevierViewall">Finally, a decrease in resistance to erythromycin (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000; 95% CI: 4.6, 53) was observed. These differences in erythromycin resistance are probably explained by the decrease of ST19A and ST14 during post-PCV13 period.</p><p id="par0150" class="elsevierStylePara elsevierViewall">Since the Spanish health system offers universal and free coverage and our hospital is the only paediatric tertiary referral hospital in the island, it is to be expected that virtually every paediatric IPD case occurring in our island during the study has been included. Therefore, it is quite likely that the incidence figures and the other results presented here are not just “estimations” but a true picture of the actual evolution of paediatric IPD in our island.</p><p id="par0155" class="elsevierStylePara elsevierViewall">On the other hand, the relatively low vaccination coverage and the small number of STs, make difficult to determine to what extent the introduction of vaccination is responsible of these changes and to interpret changes in the distribution of individual STs. However, from March 2015, pneumococcal vaccination is included in the publicly-funded, universal immunization schedule in our region. This will highly increase vaccination coverage in subsequent years.</p><p id="par0160" class="elsevierStylePara elsevierViewall">As far as we know, this is the first study to calculate the incidence of paediatric IPD in the island of Gran Canaria after PCV13 introduction and to describe its clinical and epidemiological characteristics, ST distribution, and antibiotic resistance. Additionally, it evaluates changes in these variables among the different study periods and it will conform a baseline to keep on monitoring these variables in subsequent years when vaccination coverage will increase.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Funding</span><p id="par0165" class="elsevierStylePara elsevierViewall">None.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Conflicts of interest</span><p id="par0170" class="elsevierStylePara elsevierViewall">The authors declare no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1128774" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objectives" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1062173" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1128773" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivos" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusión" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1062174" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:2 [ 0 => array:3 [ "identificador" => "sec0015" "titulo" => "Design" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Identification and serotyping" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Antibiotic susceptibility tests" ] ] ] 1 => array:2 [ "identificador" => "sec0030" "titulo" => "Statistical analysis" ] ] ] 6 => array:2 [ "identificador" => "sec0035" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0040" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0045" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0050" "titulo" => "Conflicts of interest" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-07-03" "fechaAceptado" => "2017-10-26" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1062173" "palabras" => array:5 [ 0 => "Invasive pneumococcal disease" 1 => "Childhood" 2 => "Incidence" 3 => "PCV7" 4 => "PCV13" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1062174" "palabras" => array:5 [ 0 => "Enfermedad neumocócica invasiva" 1 => "Infancia" 2 => "Incidencia" 3 => "PCV7" 4 => "PCV13" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To calculate the incidence of invasive pneumococcal disease (IPD) in the paediatric population of Gran Canaria (Spain), its clinical and epidemiological characteristics, serotype distribution, antibiotic resistance, and variations in these variables before and after the introduction of the PCV13 vaccine.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Prospective hospital-based study including all patients (190) aged 0–14 years admitted with confirmed IPD between January 2001–May 2010 (152 cases) and June 2010–December 2016 (38 cases). Patients were divided into 3 age groups (<2 years; 2–5 years; and >5 years). Clinical symptoms were mutually-exclusively classified as meningitis, bacteraemic pneumonia, pleural effusion (PE), empyema or bacteraemia without a focus.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Most cases occurred in boys (59.47%), during autumn-winter (65.79%), in children aged <2 years (55.79%) and with mean age increasing from the pre-PCV13 to the post-PCV13 period (2.5 <span class="elsevierStyleItalic">vs</span> 3.1 years). Incidence between periods reduced by 66.4% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001): from 13.1/100,000 to 4.4/100,000. PEs (3.9% <span class="elsevierStyleItalic">vs</span> 18.4%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.005) and empyemas (1.5% <span class="elsevierStyleItalic">vs</span> 16.7%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>NS) increased in the post-PCV13 period whereas all other symptoms decreased, although this was not statistically significant. Vaccine serotypes (77% <span class="elsevierStyleItalic">vs</span> 40.6%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000), particularly serotypes 19A (23.9% <span class="elsevierStyleItalic">vs</span> 12.5%) and 14 (14.2% <span class="elsevierStyleItalic">vs</span> 9.4%), as well as erythromycin resistance (57.2% <span class="elsevierStyleItalic">vs</span> 7.9%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000) decreased in the post-PCV13 period.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">IPD incidence, vaccine serotypes and erythromycin resistance decreased in the post-PCV13 period whereas PEs increased.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objectives" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivos</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Calcular la incidencia de enfermedad neumocócica invasiva (ENI) pediátrica en Gran Canaria (España), sus características clínicas y epidemiológicas, distribución de serotipos, resistencias antibióticas, y las variaciones en estas variables antes y después de la introducción de la vacuna PCV13.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio hospitalario prospectivo que incluye todos los pacientes con edades entre 0-14 años (190) ingresados con un diagnóstico confirmado de ENI entre enero 2001 – mayo 2010 (152 casos) y junio 2010 – diciembre 2016 (38 casos). Los pacientes se dividieron en 3 grupos de edad (<2 años; 2-5 años; y >5 años). Los síntomas clínicos se clasificaron de manera mutuamente exclusiva en meningitis; neumonía bacterémica, derrame pleural (DP), empiema, o bacteremia sin foco.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">La mayoría de los casos se concentró en en varones (59.47%), durante otoño-invierno (65.79%), en <2 años (55.79%) y con un aumento de la edad media entre periodos (2.5<span class="elsevierStyleItalic">vs</span>3.1 años). La incidencia entre periodos se redujo un 66.4% (P<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001): de 13.1/100,000 a 4.4/100,000. Los DPs (3.9%<span class="elsevierStyleItalic">vs</span>18.4%, P<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.005) y empiemas (1.5%<span class="elsevierStyleItalic">vs</span>16.7%, P<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>NS) aumentaron durante el periodo post-PCV13 mientras que el resto de síntomas se redujeron pero de manera no estadísticamente significativa. Los serotipos vacunales (77%<span class="elsevierStyleItalic">vs</span>40.6%, P<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000), especialmente los serotipos 19A (23.9%<span class="elsevierStyleItalic">vs</span>12.5%) y 14 (14.2%<span class="elsevierStyleItalic">vs</span>9.4%), así como la resistencia a la eritromicina (57.2%<span class="elsevierStyleItalic">vs</span>7.9%, P<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.000) se redujeron en el periodo post-PCV13.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusión</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">En el periodo post-PCV13 se redujo la incidencia de ENI, los serotipos vacunales, y la resistencia a la eritromicina mientras que aumentaron los DPs.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivos" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusión" ] ] ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 753 "Ancho" => 1692 "Tamanyo" => 79540 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Annual distribution of IPD cases and deaths.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Pre-PCV13 period (January 2001–May 2010)</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Post-PCV13 period (June 2010–December 2016)</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> (95% CI) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " rowspan="4" align="left" valign="top">Demographics</td><td class="td" title="table-entry " align="left" valign="top">Age mean (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">2.5</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">3.1</td><td class="td" title="table-entry " align="char" valign="top">0.31 (−18.3, 5.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">58.6</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">63.2</td><td class="td" title="table-entry " align="char" valign="top">0.61 (0.4, 1.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Deaths (<span class="elsevierStyleItalic">n</span>) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">8</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">0</td><td class="td" title="table-entry " align="char" valign="top">0.15 (0.9, 1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cases (<span class="elsevierStyleItalic">n</span>) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cases (<span class="elsevierStyleItalic">n</span>) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="7" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " rowspan="5" align="left" valign="top">Clinical syndromes</td><td class="td" title="table-entry " align="left" valign="top">Meningitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.83 (0.3, 2.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">35 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.33 (0.2, 1.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.005 (1.7, 17.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Empyema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.23 (0.7, 8.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Bacteremia without a focus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">53.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">42.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.19 (0.3, 1.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1924353.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0005"><span class="elsevierStyleItalic">p</span>-Value comparing pre-PCV13 and post-PCV13 periods.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Demographic characteristics and clinical syndromes of the study population.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Pre-PCV13 period (January 2001–May 2010)</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Post-PCV13 period (June 2010–December 2016)</th><th class="td" title="table-head " align="left" valign="top" scope="col"><span class="elsevierStyleItalic">p</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">*</span></a> (95% CI) \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cases (<span class="elsevierStyleItalic">n</span>) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cases (<span class="elsevierStyleItalic">n</span>) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">PCV7</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">36.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">12.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.01 (0.08, 0.76) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="7" align="left" valign="top"></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>6B \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>9V \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>18C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>19F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>23F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="6" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">PCV13 only (non-PCV7)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">40.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">28.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.22 (0.24, 1.34) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="6" align="left" valign="top"></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>6A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>7F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>19A \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">23.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">12.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="6" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">PCV13</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">87 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">77 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">40.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 (0.09, 0.47) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Non-vaccine</span><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">72 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">63.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">59.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.65 (0.37, 1.86) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1924354.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0010"><span class="elsevierStyleItalic">p</span>-Value comparing pre-PCV13 and post-PCV13 periods.</p>" ] 1 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Not included in any of the vaccine/s available in each period.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Distribution of vaccine serotypes among periods.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:19 [ 0 => array:3 [ "identificador" => "bib0100" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "DNA bacterial load in children and adolescents with pneumococcal pneumonia an empyema" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Muñoz-Almagro" 1 => "S. Gala" 2 => "L. Selva" 3 => "I. Jordan" 4 => "D. Tarragó" 5 => "R. Pallares" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10096-010-1086-9" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Microbiol Infect Dis" "fecha" => "2011" "volumen" => "30" "paginaInicial" => "327" "paginaFinal" => "335" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20972810" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0105" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Tarragó" 1 => "A. Fenoll" 2 => "D. Sánchez-Tatay" 3 => "L.A. Arroyo" 4 => "C. Muñoz-Almagro" 5 => "C. Esteva" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1469-0691.2008.02028.x" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2008" "volumen" => "14" "paginaInicial" => "828" "paginaFinal" => "834" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18844683" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0110" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Aspectos epidemiológicos de la enfermedad neumocócica invasiva antes y después del uso de la vacuna neumocócica conjugada en Gran Canaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Artiles" 1 => "I. Horcajada" 2 => "A.M. Cañas" 3 => "I. Álamo" 4 => "A. Bordes" 5 => "A. González" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2008.03.001" "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2009" "volumen" => "27" "paginaInicial" => "14" "paginaFinal" => "21" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19217998" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0115" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiología de la enfermedad invasiva neumocócica en Guipúzcoa (1981-2001)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L. Iglesias" 1 => "E. Pérez-Yarza" 2 => "J.M. García-Arenzana" 3 => "A. Valiente" 4 => "E. Pérez-Trallero" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "An Esp Pediatr" "fecha" => "2002" "volumen" => "57" "paginaInicial" => "401" "paginaFinal" => "407" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12467542" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0120" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enfermedad invasiva por <span class="elsevierStyleItalic">Streptococcus pneumoniae</span> y <span class="elsevierStyleItalic">Haemophilus influenzae</span> serotipo b, Estudio restrospectivo de 12 años" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Villó Sirerol" 1 => "J.E. Blanco González" 2 => "P. Sevilla Ramos" 3 => "E. Vegas Munoz" 4 => "M.A. Garcia Herrero" 5 => "J. Alvarez Coca" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatr (Barc)" "fecha" => "2004" "volumen" => "61" "paginaInicial" => "150" "paginaFinal" => "155" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0125" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estudio de la incidencia de enfermedad neumococica invasora entre 0-5 años en el Pais Vasco y Navarra" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "el Grupo de Estudio de Enfermedad Invasora Neumocócica en el País Vasco-Navarra" "etal" => false "autores" => array:5 [ 0 => "E. Bernaola" 1 => "J. De Aristegui" 2 => "M. Herranz" 3 => "C. García" 4 => "C. Fernández" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "An Esp Pediatr" "fecha" => "2002" "volumen" => "57" "paginaInicial" => "301" "paginaFinal" => "309" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12392663" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0130" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Casado Flores" 1 => "A. Fenoll" 2 => "J. Arístegui Fernández" 3 => "C. Rodrigo de Liria" 4 => "J.M. Martiñón Sánchez" 5 => "S. Berrón" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Esp Pediatr" "fecha" => "2002" "volumen" => "57" "paginaInicial" => "295" "paginaFinal" => "300" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0135" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre. Spain, after introduction of the heptavalent pneumococcal conjugate vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Aristegui" 1 => "E. Bernaola" 2 => "I. Pocheville" 3 => "C. García" 4 => "L. Arranz" 5 => "G. Durán" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10096-007-0294-4" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Microbiol Infect Dis" "fecha" => "2007" "volumen" => "26" "paginaInicial" => "303" "paginaFinal" => "310" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17457623" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0140" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Calbo" 1 => "A. Díaz" 2 => "E. Cañadell" 3 => "J. Fábrega" 4 => "S. Uriz" 5 => "M. Xercavins" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1469-0691.2006.1502_1.x" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2006" "volumen" => "12" "paginaInicial" => "867" "paginaFinal" => "872" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16882291" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0145" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Picazo" 1 => "J. Ruiz-Contreras" 2 => "J. Casado-Flores" 3 => "S. Negreira" 4 => "M.J. García-de-Miguel" 5 => "T. Hernández-Sampelayo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CVI.00239-13" "Revista" => array:6 [ "tituloSerie" => "Clin Vaccine Immunol" "fecha" => "2013" "volumen" => "20" "paginaInicial" => "1524" "paginaFinal" => "1530" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23925887" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0150" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Guevara" 1 => "C. Ezpeleta" 2 => "A. Gil-Setas" 3 => "L. Torroba" 4 => "X. Beristain" 5 => "A. Aguinaga" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2014.03.054" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2014" "volumen" => "32" "paginaInicial" => "2553" "paginaFinal" => "2562" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24674661" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0155" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.A. Waight" 1 => "N.J. Andrews" 2 => "S.N. Ladhani" 3 => "C.L. Sheppard" 4 => "M.P. Slack" 5 => "E. Miller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(15)70044-7" "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2015" "volumen" => "15" "paginaInicial" => "535" "paginaFinal" => "543" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25801458" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0160" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z.B. Harboe" 1 => "T. Dalby" 2 => "D.M. Weinberger" 3 => "T. Benfield" 4 => "K. Mølbak" 5 => "H.C. Slotved" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/ciu524" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2014" "volumen" => "59" "paginaInicial" => "1066" "paginaFinal" => "1073" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25034421" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0165" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Ben-Shimol" 1 => "D. Greenberg" 2 => "N. Givon-Lavi" 3 => "Y. Schlesinger" 4 => "E. Somekh" 5 => "S. Aviner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2014.03.065" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2014" "volumen" => "32" "paginaInicial" => "3452" "paginaFinal" => "3459" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24690148" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0170" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Lepoutre" 1 => "E. Varon" 2 => "S. Georges" 3 => "F. Dorléans" 4 => "C. Janoir" 5 => "L. Gutmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2014.11.011" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2015" "volumen" => "33" "paginaInicial" => "359" "paginaFinal" => "366" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25448105" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0175" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.R. Moore" 1 => "R. Link-Gelles" 2 => "W. Schaffner" 3 => "R. Lynfield" 4 => "C. Lexau" 5 => "N.M. Bennett" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2015" "volumen" => "15" "paginaInicial" => "301" "paginaFinal" => "309" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0180" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Has the incidence of empyema in Scottish children continued to increase beyond 2005?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Nath" 1 => "M. Thomas" 2 => "D. Spencer" 3 => "S. Turner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/archdischild-2014-306525" "Revista" => array:6 [ "tituloSerie" => "Arch Dis Child" "fecha" => "2015" "volumen" => "100" "paginaInicial" => "255" "paginaFinal" => "258" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25260518" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0185" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of the pneumococcal conjugate vaccine in pneumococcal parapneumonic empyema" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.L. Byington" 1 => "K. Korgenski" 2 => "J. Daly" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.inf.0000202137.37642.ab" "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2006" "volumen" => "25" "paginaInicial" => "250" "paginaFinal" => "254" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16511389" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0190" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Parapneumonic pleural effusion: an 11-year review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Deiros Bronte" 1 => "F. Baquero-Artigao" 2 => "M.J. Garcia-Miguel" 3 => "N. Hernández González" 4 => "P. Peña Garcia" 5 => "F. del Castillo Martin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatr (Barc)" "fecha" => "2006" "volumen" => "64" "paginaInicial" => "40" "paginaFinal" => "45" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/0213005X/0000003600000010/v2_201812190632/S0213005X17303221/v2_201812190632/en/main.assets" "Apartado" => array:4 [ "identificador" => "8591" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000003600000010/v2_201812190632/S0213005X17303221/v2_201812190632/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17303221?idApp=UINPBA00004N" ]
Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Original article
Paediatric invasive pneumococcal disease on the island of Gran Canaria: 16-year prospective study (2001–2016)
Enfermedad neumocócica invasiva pediátrica en la isla de Gran Canaria: estudio prospectivo durante 16 años (2001-2016)
Milagrosa Santana Hernándeza,
, Ione Ahedey Aguiar-Santanaa, Fernando Artiles Campelob, Elena Colino Gilc
Autor para correspondencia
a Unidad de Urgencias de Pediatría, Hospital Universitario Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain
b Servicio de Microbiología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
c Unidad de Enfermedades Infecciosas, Hospital Universitario Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain
Contenido relacionado
Enferm Infecc Microbiol Clin. 2018;36:605-610.1016/j.eimc.2018.07.012
Jordi Càmara, Carmen Ardanuy
Artículo
This article is available in English
Paediatric invasive pneumococcal disease on the island of Gran Canaria: 16-year prospective study (2001–2016)
Milagrosa Santana Hernández, Ione Ahedey Aguiar-Santana, Fernando Artiles Campelo, Elena Colino Gil
10.1016/j.eimc.2017.10.022Enferm Infecc Microbiol Clin. 2018;36:607-11